Physician profile
Ehsan Sadri
NPI 1114025780
$254,633.68
in general payments reported to CMS, 2019-2025
38 companies · $3,808 in 2025
The $3,808 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $49K · 2021: $20K · 2022: $13K · 2023: $13K · 2024: $22K · 2025: $3,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $7,568 · Long Term Medical Supply Or Device Loan: $4,168 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $94.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,000.00 |
| Food and Beverage | $7,567.64 |
| Long Term Medical Supply Or Device Loan | $4,168.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $94.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $56,783.52 | 2019-2025 | Tecnis Iol, Healon Duet Pro, Compact Intuitiv |
| Aerie Pharmaceuticals, INC. | $48,043.12 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25,129.33 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $21,657.90 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $19,109.11 | 2019-2025 | Cequa, Bromsite |
| Glaukos Corporation | $15,532.19 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass Stent System, Idosetr |
| Allergan, INC. | $14,991.14 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $10,449.98 | 2019-2022 | |
| Alcon Vision LLC | $6,901.88 | 2019-2025 | Clareon, Rocklatan, Argos |
| Bausch & Lomb Americas INC. | $6,391.66 | 2022-2025 | Miebo, Xiidra, Stellaris Elite |
| Ivantis, INC | $5,709.62 | 2019-2021 | |
| Eyepoint US, INC. | $5,118.17 | 2019 | |
| Carl Zeiss Meditec, INC. | $5,078.80 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $2,411.42 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $2,094.63 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $2,012.45 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Novartis Pharmaceuticals Corporation | $1,878.63 | 2019-2022 | |
| Alcon Research LLC | $1,718.07 | 2023-2025 | Ngenuity |
| Hoya Surgical Optics, INC | $745.95 | 2023 | Vivinex Gemetric |
| New World Medical,INC. | $715.95 | 2019-2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Beaver-Visitec International, INC. | $507.35 | 2021-2023 | |
| Abbvie INC. | $329.50 | 2022-2023 | Botox, Durysta |
| Carl Zeiss Meditec USA, INC. | $268.21 | 2022-2023 | Iolmaster 700, Quatera 700 |
| Dompe US, INC. | $213.99 | 2021-2025 | Oxervate |
| Shire North American Group INC | $183.07 | 2019 | |
| Amgen INC. | $162.88 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $140.08 | 2020-2023 | Tepezza |
| Heru, INC. | $119.17 | 2023 | Heru Hmd |
| Rxsight INC | $108.01 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Mallinckrodt Hospital Products INC. | $26.98 | 2021 | |
| Thea Pharma INC. | $22.63 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $19.90 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $14.10 | 2019 | |
| Optos, INC. | $13.33 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $11.56 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$39,736.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsan Sadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.